US Guidance Offers IDE Tips For Devices Targeting Brain Disease Progression
This article was originally published in SRA
The US Food and Drug Administration has issued a draft guidance to help medical device makers conduct clinical trials for products designed to slow the progress of neurological conditions1. One challenge highlighted by the agency is that changes to biomarkers measured in a study may not line up easily with disease progression.
Register for our free email digests: